Latest News

  • 22nd November 2022

    ARECOR TO COMMENCE SECOND CLINICAL TRIAL WITH AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN CANDIDATE FOR TYPE 2 DIABETES

  • 22nd November 2022

    ARECOR GRANTED KEY PATENT IN JAPAN AND SOUTH KOREA TO PROTECT PROPRIETARY INSULIN PRODUCTS AT247 AND AT278

  • 10th November 2022

    ARECOR ANNOUNCES EXCLUSIVE SPECIALTY HOSPITAL FORMULATION COLLABORATION

News

Reset
  • 22/11/2022

    ARECOR TO COMMENCE SECOND CLINICAL TRIAL WITH AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN CANDIDATE FOR TYPE 2 DIABETES

  • 22/11/2022

    ARECOR GRANTED KEY PATENT IN JAPAN AND SOUTH KOREA TO PROTECT PROPRIETARY INSULIN PRODUCTS AT247 AND AT278

  • 10/11/2022

    ARECOR ANNOUNCES EXCLUSIVE SPECIALTY HOSPITAL FORMULATION COLLABORATION

  • 01/11/2022

    TETRIS PHARMA LAUNCHES OGLUO IN GERMANY

  • 11/10/2022

    HEADLINE RESULTS FROM PHASE I CLINICAL TRIAL OF ULTRA-RAPID ACTING INSULIN CANDIDATE AT247 DEMONSTRATE SIGNIFICANTLY ACCELERATED INSULIN ABSORPTION AND EARLY EXPOSURE COMPARED TO GOLD STANDARD INSULINS NOVOLOG® AND FIASP®

  • 20/09/2022

    ARECOR PRESENTS DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 AT EASD

  • 09/08/2022

    ARECOR GRANTED EUROPEAN PATENTS PROTECTING PROPRIETARY FORMULATIONS OF HIGH CONCENTRATION HUMIRA® BIOSIMILAR

  • 04/07/2022

    ARECOR ANNOUNCES PRESENTATION AT EASD 2022 OF PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES

  • 16/06/2022

    ARECOR ANNOUNCES EXCLUSIVE COLLABORATION WITH A TOP 5 GLOBAL PHARMACEUTICAL COMPANY

  • 18/05/2022

    ARECOR TO HOST KOL WEBINAR ON THE NEED FOR CONCENTRATED AND RAPID ACTING INSULIN TREATMENTS IN DIABETES CARE

  • 28/04/2022

    ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING

  • 12/04/2022

    ARECOR ANNOUNCES ORAL PRESENTATION AT ATTD 2022 OF PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING, INSULIN FOR DIABETES

  • 28/03/2022

    ARECOR WINS INNOVATION IN BUSINESS AND BUSINESS PERSON OF THE YEAR AWARDS AT THE CAMBRIDGESHIRELIVE BUSINESS AWARDS

  • 23/03/2022

    ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS

  • 20/01/2022

    ARECOR COMMENCES US PHASE I CLINICAL TRIAL OF AT247 ULTRA-RAPID INSULIN IN COMBINATION WITH AN INSULIN PUMP